Upjohn Company Profile

What is the competitive landscape for UPJOHN, and when can generic versions of UPJOHN drugs launch?

UPJOHN has thirteen approved drugs.

There are three US patents protecting UPJOHN drugs.

There are thirty-three patent family members on UPJOHN drugs in thirty-three countries and thirty-nine supplementary protection certificates in thirteen countries.

Summary for Upjohn

International Patents:	33
US Patents:	3
Tradenames:	12
Ingredients:	9
NDAs:	13

Drugs and US Patents for Upjohn

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Upjohn	CELEBREX	celecoxib	CAPSULE;ORAL	020998-004	Dec 15, 2006	AB	RX	Yes	No
Upjohn	XANAX XR	alprazolam	TABLET, EXTENDED RELEASE;ORAL	021434-004	Jan 17, 2003	AB	RX	Yes	Yes
Upjohn	RELPAX	eletriptan hydrobromide	TABLET;ORAL	021016-002	Dec 26, 2002	AB	RX	Yes	Yes
Upjohn	DETROL	tolterodine tartrate	TABLET;ORAL	020771-002	Mar 25, 1998	AB	RX	Yes	Yes
Upjohn	LYRICA	pregabalin	CAPSULE;ORAL	021446-004	Dec 30, 2004	AB	RX	Yes	No
Upjohn	LYRICA CR	pregabalin	TABLET, EXTENDED RELEASE;ORAL	209501-001	Oct 11, 2017	AB	RX	Yes	No	9,144,559*PED				Y
Upjohn	EFFEXOR XR	venlafaxine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	020699-004	Oct 20, 1997	AB	RX	Yes	Yes

Expired US Patents for Upjohn

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Upjohn	INSPRA	eplerenone	TABLET;ORAL	021437-001	Sep 27, 2002	6,495,165*PED
Upjohn	LIPITOR	atorvastatin calcium	TABLET;ORAL	020702-001	Dec 17, 1996	5,273,995*PED
Upjohn	DETROL LA	tolterodine tartrate	CAPSULE, EXTENDED RELEASE;ORAL	021228-002	Dec 22, 2000	6,770,295*PED
Upjohn	LYRICA	pregabalin	CAPSULE;ORAL	021446-005	Dec 30, 2004	5,563,175
Upjohn	LIPITOR	atorvastatin calcium	TABLET;ORAL	020702-002	Dec 17, 1996	6,126,971*PED
Upjohn	DETROL	tolterodine tartrate	TABLET;ORAL	020771-002	Mar 25, 1998	5,382,600*PED
Upjohn	XANAX	alprazolam	TABLET;ORAL	018276-003	Approved Prior to Jan 1, 1982	3,987,052

Paragraph IV (Patent) Challenges for UPJOHN drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Extended-release Tablets	37.5 mg, 75 mg and 150 mg		2007-05-03
	Capsules	25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg		2008-12-30
	Extended-release Tablets	330 mg		2018-01-29
	Extended-release Tablets	330 mg		2018-01-29
	Tablets	25 mg and 50 mg		2006-09-27
	Extended-release Capsules	2 mg and 4 mg		2007-07-30
	Capsules	50 mg		2008-03-21
	Oral Solution	20 mg/mL		2010-05-19
	Extended-release Tablets	82.5 mg and 165 mg		2018-02-02
	Extended-release Tablets	82.5 mg and 165 mg		2018-02-02
	Tablets	20 mg and 40 mg		2010-03-29

International Patents for Upjohn Drugs

Country	Patent Number	Estimated Expiration
Canada	2628200
New Zealand	567414
Poland	1945186
Dominican Republic	P2006000241
Guatemala	200600474
South Africa	200803115
Hong Kong	1126394

Supplementary Protection Certificates for Upjohn Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0247633	C970034	Netherlands		PRODUCT NAME: ATORVASTATINUM,DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF VAN HET INWENDIGE DELTA-LACTON, IN HET BIJZONDER ATORVASTATINUM CALCICUM TRIHYDRICUM; NAT. REGISTRATION NO/DATE: RVG 21081 - RVG 21083 19970421; FIRST REGISTRATION: GB PL 00018/0240 - PL 00018/0242 19961107
3461484	301101	Netherlands		PRODUCT NAME: LATANOPROST OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN NETARSUDILMESYLAAT; REGISTRATION NO/DATE: EU/1/20/1502 20210108
3461484	132021000000068	Italy		PRODUCT NAME: COMBINAZIONE DI LATANOPROST E NETARSUDIL(ROCLANDA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/20/1502, 20210108
0364417	97C0111	Belgium		PRODUCT NAME: LATANOPROSTUM; NAT. REGISTRATION NO/DATE: 277 IS 271 F 13 19970617; FIRST REGISTRATION: SE 12716 1996071
0720599	92545	Luxembourg		PRODUCT NAME: EZETIMIBE EN COMBINAISON AVEC ATORVASTATINE OU LEURS SELS PHARMACEUTIQUEMENT ACCEPTEES, Y COMPRIS ATORVASTATINE SOUS FORME D'ATORVASTATINE CALCIQUE TRIHYDRATEE; FIRST REGISTRATION: 20140910
0122232	2004C/008	Belgium		PRODUCT NAME: EPLERENONE; NATIONAL REGISTRATION NO/DATE: 241 IS 188 F3 20041220; FIRST REGISTRATION: NL RVG 29963 20040316
0247633	62/1997	Austria		PRODUCT NAME: ATORVASTATIN CALCIUM; NAT. REGISTRATION NO/DATE: 1-21926, 1-21927, 1-21928 19970411; FIRST REGISTRATION: GB PL 00018/0240 - PL 00018/0242 19961107

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Upjohn